Radiation treatment added to injections for PCV from AMD
Treatments studied
Part of Eyes & vision clinical trials.
This Phase 3 study tests whether adding a specific radiation treatment to the eye (near the outside of the eyeball) improves outcomes for people with PCV caused by AMD who haven’t responded enough to anti-VEGF injections. It may help reduce abnormal vessel activity when standard injection treatment isn’t working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active PCV that is being caused by nAMD (AMD with a specific subtype called nAMD).
- Your anti-VEGF eye injections have not worked well enough yet (incomplete response).
- You’ve had at least 3 injections in a row without missing any scheduled treatments.
- Your eye specialist says you are able to have the study’s ESB procedure (this added radiation treatment).
- Your study eye vision is not too poor (better than 20 ETDRS letters, roughly better than 20/400 Snellen).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
This trial tests a new dose of aflibercept given on different schedules for people with PCV, a type of vision loss. It aims to see which schedule works best and how long the benefit lasts.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.